Humanigen — KaloBios Pharmaceuticals — Investor Presentation (April 2017)
28 slides from Humanigen's investor presentation, Apr 20, 2017
Slide 1: Near-Term Value Creation for Neglected and Rare Diseases Through Innovative Business Models
Near-Term Value Creation for Neglected and Rare Diseases Through Innovative Business Models OTC: KBIO www.kalobios.com | Corporate Overview April 20, 2017 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements | Corporate Overview 2 This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and ex
Slide 3: Unique Investment Opportunity
Turnaround story focused on delivering value to shareholders Clinical stage neglected and rare disease assets with clear development pathway and modest investment needed to reach potentially significant value inflection pointsBenznidazole franchise: potential approval with market exclusivity plus po
Slide 4: Leadership
Leadership Cameron Durrant, MD, MBAChairman and CEOSenior pharmaceutical and biotech exec, turnaround specialistSenior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groupsExpertise in anti-infectives, pe
Slide 5: Management Experience Developing And Launching Relevant Products
Management Experience Developing And Launching Relevant Products | Corporate Overview 5
Slide 6: Two-Pronged Value Model: Near-Term Return, Propelling Long-Term Value Creation
Two-Pronged Value Model: Near-Term Return, Propelling Long-Term Value Creation | Corporate Overview 6 Smart Investment in underappreciated assets: speed to market and unmet need in neglected and rare/orphan areas Leverage Existing FDA incentives for efficiency: 505(b)(2), Orphan, Priority Review, Fa
Slide 7: Current Pipeline
Current Pipeline | Corporate Overview 7 Pre-clin Phase I Phase II Phase III NDA/BLA Benznidazole (potential PRV)Chagas diseaseAnti-infective LenzilumabCMML Anti-GM-CSF mAb Lenzilumab (potential PRV)JMML (peds) – dependent on interim data in CMMLAnti-GM-CSF mAb Ifabotuzumab (potential PRV)Solid (peds
Slide 8: Benznidazole a potential treatment for Chagas disease (CD)
Benznidazole a potential treatment for Chagas disease (CD) | Corporate Overview 8
Slide 9: Chagas disease: neglected tropical disease presenting in the US and other nations
Neglected tropical disease presenting in the US and other nations On FDA list of NTDs eligible for PRVCurrently no FDA-approved treatmentsImmediate need for reliable benznidazole supply in US and abroad CHAGAS disease | Corporate Overview 9 Insect carries the parasite called Trypanosoma cruzi Infect
Slide 10: Benznidazole: the Preferred Treatment Globally for Chagas
Benznidazole: the Preferred Treatment Globally for Chagas | Corporate Overview 10 N N HN N
Slide 11: Benznidazole Strategy, Development Plan on Track
Benznidazole Strategy, Development Plan on Track | Corporate Overview 11 Positive FDA Guidance 505(b)(2) Pathway PRV Eligibility Confirmed Progress to Submission Received minutes from productive meeting December 6, 2016 Acceptable to FDAExpect no clinical efficacy or safety studies Currently expecte
Slide 12: Benznidazole Target Approval Plan
2016 2017 H1 H2 H1 H2 Manufacturing (CMC) Analytical methods development Drug substance Drug product Stability studies Non-Clinical (Non-Human) Metabolism / PK Toxicity assessment T.cruzi biology Environmental assessment Clinical Summary of relevant clinical studies Right of Reference & data extract
Slide 13: Benznidazole Franchise Could Generate Significant Value
Benznidazole Franchise Could Generate Significant Value – Several Potential Drivers Following FDA Approval | Corporate Overview 13 U.S. PRV:Estimated $125-250MM deal potential- possible late 2018 realization U.S. Commercialization:Estimated $50-100M peak sales potential*- 20,000 patients LATAM Licen
Slide 14: The Burden of Chagas Disease in the US: ~350,000 patients
The Burden of Chagas Disease in the US: ~350,000 patients *Sources: Bern and Montgomery 2009, Manne-Goehler et al. 2016 Autocthonous cases:Number unknown Latin American-born residents:: estimated ~350,000+* *Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ (2016) Estimating the Burden of Chagas Dis
Slide 15: Building The Benznidazole Franchise: US Commercial
Building The Benznidazole Franchise: US Commercial Targeted approach to focus on key US regions with higher prevalence: CA, TX, FL, NY, VABuild Awareness to screen and test among Hispanic population and targeted clinics, health centers as well as key specialists (key CV and ID physicians); partnerin
Slide 16: Building The Benznidazole Franchise: LATAM Commercial
Building The Benznidazole Franchise: LATAM Commercial 8-10 million estimated patients, 120 million people at risk, 300,000 new cases a year, 12-14,000 deaths Large volume, lower cost commercial opportunity vs. US; potential for pricing differentiation with multiple KBIO benz versions according to ma
Slide 17: Building The Benznidazole Franchise: LCM Possibilities (Not Prioritized)
Building The Benznidazole Franchise: LCM Possibilities (Not Prioritized) Could Add Upside To US and LATAM Commercial Longer length of dosing than 60 days in some patient typesOnce daily dosing formulations vs. twice or three times dailyOnce monthly or one-time only (oral? parenteral?)Orally dispersi
Slide 18: Priority Review Voucher (PRV) May Create Options for Significant Potential Return
Building The Benznidazole Franchise: Priority Review Voucher (PRV) May Create Options for Significant Potential Return | Corporate Overview 18 Range of disclosed sale prices for PRVs is $67.5MM - $350MM Rare Pediatric Diseases (RPD) Neglected Tropical Diseases (NTD) Holder of PRV can receive priorit
Slide 19: Benznidazole Franchise Conclusions
Benznidazole Franchise Conclusions Comprises US commercial (+/- HF linkages), LATAM commercial, manufacturing potential partnerships, LCM upside and PRV saleUS commercial footprint may allow for leverage with synergistic products and is small, focused and scalable Overall package valuable and signif
Slide 20: Lenzilumab a potential pipeline in a product
Lenzilumab a potential pipeline in a product | Corporate Overview 20
Slide 21: CMML overview
High unmet needPatients typically unsuitable for stem cell transplant40-90% patients show hypersensitivity to GM-CSF CMML overview | Corporate Overview 21 Recently classified as separate disease with distinct natural history* Median overall survival rate in months Newly diagnosed US patients per yea
Slide 22: JMML overview
No FDA-approved treatmentClear unmet needPotential for a rare pediatric disease PRVGM-CSF hypersensitivity is hallmarkPediatric oncology largely ignored in clinical development JMML overview | Corporate Overview 22 Event-free survival rate at 5 years (with bone marrow transplant) New US cases per ye
Slide 23: Relatively Low Investment To Lenzilumab Inflection Point
Relatively Low Investment To Lenzilumab Inflection Point | Corporate Overview 23 2017 2018 Q1 Q2 Q3 Q4 Q1 Q2 Apply: JMML Orphan Drug, Fast Track, Rare Pediatric status CMML Phase 1 interim data analysis FDA approval of JMML protocol; clinical drug supply available JMML Phase 1 study start CMML trial
Slide 24: Building The Lenzilumab Franchise: Intentional Choices Of What To Develop
Building The Lenzilumab Franchise: Intentional Choices Of What To Develop To What Stage And What To Partner; SC Formulation Develop CMML to interim data read Q4 2017Pivot to JMML and retain and develop to approval or partner prior, but keep interest in any potential PRV sale proceedsDevelop in Cytok
Slide 25: Lenzilumab Franchise Conclusions
Lenzilumab Franchise Conclusions Comprises US development and partnering, ex-US partnering, US focused Orphan commercial, LCM upside and PRV saleUS commercial Orphan footprint could be scaled independently or via partnerships Potential opportunity to benefit from CAR-T interest US and ex-US ultra-Or
Slide 26: Benznidazole and lenzilumab franchises; new management
Benznidazole franchise- Potential approval with market exclusivity plus potential PRV sale in 2018 - Standalone, highly-focused commercial product launch in US post-approval; partnership opps- 2019 commercial infrastructure can be leveraged with synergistic products- Large market in LATAM - LCM plan
Slide 27: Capitalization Summary as of 4/12/17
Capitalization Summary as of 4/12/17 | Corporate Overview 27 Debt $10.1 million Common Shares Outstanding 15.0 million Stock Options (WAEP $4.15) 1.8 million Warrants (WAEP $13.52) 0.4 million Fully Diluted Shares Outstanding 17.2 million Note: share and per share amounts as of 12/31/16 Debt include
Slide 28: Summary
Summary Attractive asset portfolio with potential to deliver shareholder value quicklyUnique near-term/long-term potential value creation opportunity Business strategy that leverages existing U.S. regulatory and development incentives to build unique, high value franchises around key assetsDeeply fo
KaloBios Pharmaceuticals — Investor Presentation (April 2017) on 6ix